Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:30:46 28/06/2024 am IST			5-day change	1st Jan Change
129.8 ^USD	-1.28%		+0.12%	+19.08%

27/06	FDA Turns Away Daiichi Sankyo, Merck Lung-Cancer ADC	DJ
27/06	US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	RE

Declaration of Voting Results by Merck & Co

May 31, 2024 at 01:44 am IST

On May 30, 2024, Merck & Co., Inc announced that it held its annual general meeting of shareholders on May 28, 2024, and declared voting results. Accordingly, a shareholder proposal regarding a report on respecting workforce civil liberties submitted by Alliance Defending Freedom was not approved by the Company shareholders.

Latest news about Merck & Co., Inc.

FDA Turns Away Daiichi Sankyo, Merck Lung-Cancer ADC	27/06	DJ
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	27/06	RE
Merck: FDA response on patritumab deruxtecan	27/06	CF
Aqilion Announces the Termination of the Licensing and Collaboration Agreement with Merck for the Joint Development of the TAK1 Programme Taking Aim at Chronic Inflammation	27/06	CI
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer	27/06	CI
Merck: US approval for canine flu vaccine	26/06	CF
Merck's Animal Health Unit Says USDA Approves Dog Flu Vaccine	26/06	MT
Merck Animal Division's Dog Flu Treatment Gets Agriculture Department Approval	26/06	DJ
China grants license to Merck's KEYTRUDA for stomach cancer treatment	25/06	RE
Global markets live: Shell, UBS, Boeing, Berkshire Hathaway, Exxon...	18/06
Merck: FDA approves Capvaxive pneumococcal vaccine	18/06	CF
Merck: new FDA approval for Keytruda	18/06	CF
Big tech still runs the show	18/06
Sector Update: Health Care Stocks Flat to Lower Premarket Tuesday	18/06	MT
Wall Street set for flat open after soft retail sales data	18/06	RE
Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals	18/06	MT
Merck Gets FDA Approval for Keytruda Plus Carboplatin and Paclitaxel for Endometrial Carcinoma Treatment	18/06	MT
Merck Get FDA Approval for Keytruda to Treat Endometerial Cancer	18/06	DJ
US FDA approves Merck's pneumococcal vaccine for adults	18/06	RE
Merck Announces U.S. FDA Approves Capvaxive (Pneumococcal 21-Valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults	18/06	CI
Merck Announces FDA Approves Merck's Keytruda (Pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma	18/06	CI
FDA Approves Merck's Vaccine For Adult Invasive Pneumococcal Disease	18/06	DJ
High-risk health workers can get routine Ebola vaccine, Gavi says	13/06	RE
AbbVie inks immune disorder drug licensing deal with China's FutureGen	13/06	RE
High-risk health workers can get routine Ebola vaccine, says Gavi	13/06	RE

Chart Merck & Co., Inc.

Duration

Period

More charts

Company Profile

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).

Sector

Pharmaceuticals

Calendar

30/07/2024 - Q2 2024 Earnings Release

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Merck & Co., Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

129.8 USD

Average target price

142.7 USD

Spread / Average Target

+9.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MERCK & CO., INC.	+19.08%	333B
ELI LILLY AND COMPANY	+55.95%	811B
NOVO NORDISK A/S	+43.62%	640B
JOHNSON & JOHNSON	-6.98%	353B
ABBVIE INC.	+9.05%	302B
ASTRAZENECA PLC	+16.30%	246B
ROCHE HOLDING AG	+2.41%	225B
NOVARTIS AG	+12.47%	218B
AMGEN INC.	+8.91%	168B
PFIZER, INC.	-3.44%	155B

Other Pharmaceuticals

Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Declaration of Voting Results by Merck & Co

EPS Revisions